CN113967117A - Degradable magnesium alloy drug eluting stent - Google Patents
Degradable magnesium alloy drug eluting stent Download PDFInfo
- Publication number
- CN113967117A CN113967117A CN202010718662.8A CN202010718662A CN113967117A CN 113967117 A CN113967117 A CN 113967117A CN 202010718662 A CN202010718662 A CN 202010718662A CN 113967117 A CN113967117 A CN 113967117A
- Authority
- CN
- China
- Prior art keywords
- eluting stent
- magnesium alloy
- support
- degradable magnesium
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910000861 Mg alloy Inorganic materials 0.000 title claims abstract description 25
- 239000003814 drug Substances 0.000 title description 27
- 229940079593 drug Drugs 0.000 title description 25
- 230000007423 decrease Effects 0.000 claims abstract description 5
- 230000015556 catabolic process Effects 0.000 abstract description 8
- 238000006731 degradation reaction Methods 0.000 abstract description 8
- 230000007547 defect Effects 0.000 abstract description 4
- 210000004204 blood vessel Anatomy 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 101100334009 Caenorhabditis elegans rib-2 gene Proteins 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheets or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/9155—Adjacent bands being connected to each other
- A61F2002/91575—Adjacent bands being connected to each other connected peak to trough
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Physics & Mathematics (AREA)
- Vascular Medicine (AREA)
- Optics & Photonics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明提供的可降解镁合金药物洗脱支架，属于医疗器械技术领域，包括：包括间隔设置的多个支撑环，相邻两个所述支撑环之间通过多个连接键连接；所述支撑环为多个支架桥筋依次镜像连接构成的波浪形结构，所述支架桥筋两端分别具有朝向外侧凸起的弧形段，所述支架桥筋的宽度由两端到中间逐步递减。本发明的支架桥筋的宽度由两端到中间逐步递减，使两端处的强度大于中间处的强度，能够平衡两端处因应力集中受损而加快降解速率的情况，从而避免支架整体降解不均匀而过早失去支撑能力的缺陷。
The degradable magnesium alloy drug-eluting stent provided by the invention belongs to the technical field of medical devices, and includes: a plurality of supporting rings arranged at intervals, and two adjacent supporting rings are connected by a plurality of connecting keys; The ring is a wave-shaped structure formed by mirrored connection of a plurality of support bridge ribs in sequence, the two ends of the support bridge ribs respectively have arc segments that protrude toward the outside, and the width of the support bridge ribs gradually decreases from the two ends to the middle. The width of the support bridge bars of the present invention gradually decreases from the two ends to the middle, so that the strength at the two ends is greater than that at the middle, which can balance the accelerated degradation rate due to stress concentration damage at the two ends, thereby avoiding the overall degradation of the support. A defect that is uneven and loses its ability to support prematurely.
Description
Technical Field
The invention relates to the technical field of medical instruments, in particular to a degradable magnesium alloy drug eluting stent.
Background
Drug eluting stents, also known as drug releasing stents, carry the drug through a polymer coated on the surface of a metal stent; when the stent is implanted into a diseased part in a blood vessel, the medicine is controllably released from the polymer coating to a blood vessel wall tissue in an elution mode to play a biological effect, so that the formation of atheromatous plaques in the blood vessel is inhibited, and the stenosis degree of the blood vessel is improved; when the drug release in the coating is finished, the stent begins to degrade slowly, and finally the stent is degraded completely, and the blood vessel is recovered to be normal.
The magnesium alloy support structures on the market at present are various, most of the supports are in the expansion process, stress concentration and damage phenomena of different degrees are easily shown on the support rings due to different stress of all parts, and the integral bearing capacity of the support is reduced, even the support loses the supporting force too early.
Disclosure of Invention
Therefore, the technical problem to be solved by the invention is to overcome the defects that the bearing capacity is reduced and even the supporting force is lost too early due to uneven stress of each part of the stent in the expansion process in the prior art, thereby providing the degradable magnesium alloy crown elution stent.
In order to solve the technical problems, the degradable magnesium alloy coronary medicine elution stent provided by the invention comprises:
the support rings are arranged at intervals, and every two adjacent support rings are connected through a plurality of connecting keys;
the support ring is the wave structure that a plurality of support bridge muscle mirror image connection constitutes in proper order, support bridge muscle both ends have respectively towards outside bellied arc section, the width of support bridge muscle is progressively steadilyd decrease from both ends to the centre.
Preferably, the connecting key is located between the minimum spacing of two adjacent support rings.
Preferably, the two adjacent support rings are arranged in a mirror symmetry manner.
Preferably, the connecting key has an S-shaped structure.
Preferably, the connecting bond includes:
a plurality of support rings connected between two ends of the drug eluting stent and the adjacent support rings, wherein the first connecting key is provided with a preformed hole suitable for embedding a developing sheet;
and the second connecting keys are provided with a plurality of S-shaped structures and are connected between two adjacent columns of the support rings between the first connecting keys.
Preferably, the linkages are helically distributed on the drug eluting stent.
Preferably, the width of the two ends of the bridge rib of the bracket is 150-190 μm, and the width of the middle part of the bridge rib of the bracket is 70-100 μm.
The technical scheme of the invention has the following advantages:
1. according to the degradable magnesium alloy drug eluting stent provided by the invention, the bridge ribs of the stent are sequentially connected in a mirror image manner, and the joints are in arc transition, so that the flexibility of the support ring is improved; in the expansion process, the bending degree of the arc transition part of the support ring is maximum, so that the stress concentration degree is maximum, namely the stress concentration degree of the support bridge rib is gradually increased from the middle to the two ends; the width of the bridge rib of the support is gradually decreased from two ends to the middle, so that the strength of the two ends is greater than that of the middle, the condition that the degradation rate is accelerated due to stress concentration damage at the two ends can be balanced, and the defect that the support capacity is prematurely lost due to uneven integral degradation of the support is avoided.
2. According to the degradable magnesium alloy drug eluting stent provided by the invention, the vertical distance of the connecting bond is equal to the minimum distance between two adjacent support rings, so that the radial ductility of the stent is increased, and the stent can be rapidly expanded after reaching a patient position.
3. According to the degradable magnesium alloy drug eluting stent provided by the invention, two adjacent support rings are arranged in a mirror symmetry manner, so that the support rings are uniformly stressed and synchronously degraded.
4. According to the degradable magnesium alloy drug eluting stent provided by the invention, the connecting bond adopts an S-shaped structure, so that the metal surface coverage rate of the whole stent is increased compared with that of a straight line structure; the flexibility of the whole stent is increased, and proper axial retraction supplement can be provided when the stent is expanded.
5. According to the degradable magnesium alloy drug eluting stent provided by the invention, the developing sheet is additionally arranged at the reserved hole of the first connecting key, so that the integral visibility of the stent is improved, and the degradation condition of the stent is convenient to observe.
6. According to the degradable magnesium alloy drug eluting stent provided by the invention, the connecting bonds are spirally distributed on the stent, so that the stress of the whole stent is more balanced and the passing performance is better.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, and it is obvious that the drawings in the following description are some embodiments of the present invention, and other drawings can be obtained by those skilled in the art without creative efforts.
Fig. 1 is a schematic deployment view of a degradable magnesium alloy drug eluting stent provided in the present invention.
Fig. 2 is a schematic structural diagram of a stent bridge rib.
Description of reference numerals:
1. a support ring; 2. a bracket bridge rib; 3. a first connecting key; 4. a second connecting key; 5. wave crest; 6. a trough of a wave; 7. holes are reserved.
Detailed Description
The technical solutions of the present invention will be described clearly and completely with reference to the accompanying drawings, and it should be understood that the described embodiments are some, but not all embodiments of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
In the description of the present invention, it should be noted that the terms "center", "upper", "lower", "left", "right", "vertical", "horizontal", "inner", "outer", etc., indicate orientations or positional relationships based on the orientations or positional relationships shown in the drawings, and are only for convenience of description and simplicity of description, but do not indicate or imply that the device or element being referred to must have a particular orientation, be constructed and operated in a particular orientation, and thus, should not be construed as limiting the present invention.
In the description of the present invention, it should be noted that, unless otherwise explicitly specified or limited, the terms "mounted," "connected," and "connected" are to be construed broadly, e.g., as meaning either a fixed connection, a removable connection, or an integral connection; can be mechanically or electrically connected; they may be connected directly or indirectly through intervening media, or they may be interconnected between two elements. The specific meanings of the above terms in the present invention can be understood in specific cases to those skilled in the art.
In addition, the technical features involved in the different embodiments of the present invention described below may be combined with each other as long as they do not conflict with each other.
The degradable magnesium alloy drug eluting stent provided by the embodiment is formed by laser fusion etching of a magnesium alloy ultrathin tube, and comprises: the drug eluting stent comprises support rings 1 and connecting keys connected among the support rings 1, wherein the drug eluting stent is in a tubular structure formed by encircling the support rings 1.
As shown in fig. 1, which is a development view of a drug eluting stent, the support ring 1 is formed into a wave-shaped structure by connecting a plurality of stent bridge ribs 2 in sequence in a mirror image manner; the support rings 1 are vertically arranged at intervals from left to right, and the adjacent two support rings 1 are arranged in a mirror symmetry manner, so that the support rings 1 are uniformly stressed and synchronously degraded; the support bridge rib 2 is of a centrosymmetric structure, and two ends of the support bridge rib are respectively provided with an arc-shaped section protruding towards the outer side; the arc sections of two adjacent support bridge ribs 2 are in transitional connection, and a plurality of wave crests 5 and wave troughs 6 are sequentially formed on the support ring 1.
As shown in fig. 1, the wave troughs 6 of adjacent support rings 1 are opposite, and the distance between two adjacent wave troughs 6 is the minimum distance between two support rings 1; the connecting key is connected adjacent two between the trough 6 of support ring 1, and adjacent support ring 1 is between the quantity of connecting key is two, is favorable to the radial expansion of support. The connecting keys comprise a first connecting key 3 and a second connecting key 4; the number of the first connecting keys 3 is four, every two of the first connecting keys are divided into a group and are respectively connected between the support rings 1 at two ends of the drug eluting stent and the adjacent support rings 1; first connecting key 3 is circular structure, and center department sets up the preformed hole 7 that is suitable for the scarf joint development piece, the development piece can promote the holistic visuality of support, is convenient for observe the holistic degradation condition of support in real time. The second connecting keys 4 are S-shaped structures and are connected between two adjacent columns of the support rings 1 positioned between the first connecting keys 3; the S-shaped structure of the second connecting bond 4 increases the metal surface coverage rate of the whole stent, and the metal surface coverage rate of the expanded drug eluting stent is not higher than 20%; the S-shaped configuration of the second bonds 4 also increases the overall flexibility of the drug eluting stent, providing for proper axial recoil replenishment during stent expansion.
As shown in fig. 1, the connecting bonds are spirally distributed on the drug eluting stent, and the connecting lines at the positions of the connecting bonds are represented by equally spaced oblique lines on the development view of the drug eluting stent; the connecting keys are distributed on the bracket in a spiral shape, so that the stress of the whole bracket is more balanced, and the passing performance is better.
As shown in fig. 2, the width of the stent bridge rib 2 gradually decreases from the middle to the two ends, so that the strength at the two ends is greater than that at the middle, wherein the width D1 at the two ends is 150-190 μm, and the width D2 at the middle is 70-100 μm; in the expansion process of the support ring 1, the wider design at the two ends of the support bridge rib 2 can balance the condition that the degradation rate is accelerated due to stress concentration damage at the two ends, so that the defect that the support capability is lost too early due to the uneven degradation of the whole support is avoided.
It should be understood that the above examples are only for clarity of illustration and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. And obvious variations or modifications therefrom are within the scope of the invention.
Claims (9)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010718662.8A CN113967117A (en) | 2020-07-23 | 2020-07-23 | Degradable magnesium alloy drug eluting stent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010718662.8A CN113967117A (en) | 2020-07-23 | 2020-07-23 | Degradable magnesium alloy drug eluting stent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113967117A true CN113967117A (en) | 2022-01-25 |
Family
ID=79585365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010718662.8A Pending CN113967117A (en) | 2020-07-23 | 2020-07-23 | Degradable magnesium alloy drug eluting stent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113967117A (en) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6190406B1 (en) * | 1998-01-09 | 2001-02-20 | Nitinal Development Corporation | Intravascular stent having tapered struts |
| US20110238157A1 (en) * | 2008-11-04 | 2011-09-29 | Microport Medical (Shanghai) Co., Ltd. | Coronary artery vascular stent with medicine carrying slots |
| CN103391757A (en) * | 2011-03-03 | 2013-11-13 | 波士顿科学国际有限公司 | Low strain high strength stent |
| US20130304191A1 (en) * | 2010-11-12 | 2013-11-14 | Xu Cai | Stent for a bifurcated vessel |
| US20140114434A1 (en) * | 2012-10-22 | 2014-04-24 | Orbusneich Medical, Inc. | Medical device for implantation into luminal structures |
| US20150112422A1 (en) * | 2013-10-22 | 2015-04-23 | Orbusneich Medical, Inc. | Medical Device for Implantation into Luminal Structures Incorporating Corrugated Structural Elements |
| US20170172769A1 (en) * | 2015-12-17 | 2017-06-22 | Abbott Cardiovascular Systems Inc. | Thin-walled scaffolds having reduced crimp profile and carrying radiopaque markers. |
| US20170203494A1 (en) * | 2014-07-07 | 2017-07-20 | Meril Life Sciences Pvt. Ltd. | Method to manufacture thin strut stent from bioabsorbable polymer with high fatigue and radial strength |
| CN108578025A (en) * | 2018-04-20 | 2018-09-28 | 江苏大学 | A kind of balloon-expandable intravascular stent for taking into account compliance and supportive |
| CN212522101U (en) * | 2020-07-23 | 2021-02-12 | 赛诺医疗科学技术股份有限公司 | Degradable magnesium alloy drug eluting stent |
-
2020
- 2020-07-23 CN CN202010718662.8A patent/CN113967117A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6190406B1 (en) * | 1998-01-09 | 2001-02-20 | Nitinal Development Corporation | Intravascular stent having tapered struts |
| US20110238157A1 (en) * | 2008-11-04 | 2011-09-29 | Microport Medical (Shanghai) Co., Ltd. | Coronary artery vascular stent with medicine carrying slots |
| US20130304191A1 (en) * | 2010-11-12 | 2013-11-14 | Xu Cai | Stent for a bifurcated vessel |
| CN103391757A (en) * | 2011-03-03 | 2013-11-13 | 波士顿科学国际有限公司 | Low strain high strength stent |
| US20140114434A1 (en) * | 2012-10-22 | 2014-04-24 | Orbusneich Medical, Inc. | Medical device for implantation into luminal structures |
| US20150112422A1 (en) * | 2013-10-22 | 2015-04-23 | Orbusneich Medical, Inc. | Medical Device for Implantation into Luminal Structures Incorporating Corrugated Structural Elements |
| US20170203494A1 (en) * | 2014-07-07 | 2017-07-20 | Meril Life Sciences Pvt. Ltd. | Method to manufacture thin strut stent from bioabsorbable polymer with high fatigue and radial strength |
| US20170172769A1 (en) * | 2015-12-17 | 2017-06-22 | Abbott Cardiovascular Systems Inc. | Thin-walled scaffolds having reduced crimp profile and carrying radiopaque markers. |
| CN108578025A (en) * | 2018-04-20 | 2018-09-28 | 江苏大学 | A kind of balloon-expandable intravascular stent for taking into account compliance and supportive |
| CN212522101U (en) * | 2020-07-23 | 2021-02-12 | 赛诺医疗科学技术股份有限公司 | Degradable magnesium alloy drug eluting stent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004508883A (en) | Intravascular stent device | |
| JP6220386B2 (en) | Uniformly expandable stent | |
| JP2004508882A (en) | Intravascular stent device | |
| CN106456347B (en) | Reduce the support Design of granulation and inflammation | |
| TW539559B (en) | Stent with optimal strength and radiopacity characteristics | |
| JP5259746B2 (en) | Lumen prosthesis | |
| WO2019096158A1 (en) | Endovascular stent | |
| MX2007005168A (en) | Stent having phased hoop sections. | |
| CN102068331A (en) | Bifurcate blood vessel stent | |
| WO2009137993A1 (en) | Net-like and intravascular stent | |
| CN112089511B (en) | A self-expanding tapered vascular stent for multiple stenosis of tapered blood vessels | |
| CN1640505A (en) | Sine-wave tubular medical interventional stent | |
| CN112089512A (en) | Balloon expansion type intravascular stent applied to multiple stenosis of circular and straight blood vessels | |
| CN212522101U (en) | Degradable magnesium alloy drug eluting stent | |
| CN113967117A (en) | Degradable magnesium alloy drug eluting stent | |
| WO2014030982A1 (en) | Wire stent | |
| CN112107401A (en) | Support suitable for crooked position of urethra | |
| CN111789705A (en) | bracket | |
| CN117224297A (en) | Lower limb artery stent with reverse combined structure | |
| CN105769398A (en) | Biodegradable vascular stent based on polyhedron deformation mechanism | |
| CN222828701U (en) | Vascular stents | |
| WO2022267889A1 (en) | Stent | |
| CN113648113B (en) | Degradable support | |
| CN108553206A (en) | Intravascular stent and blood vessel coating bracket | |
| CN118267208B (en) | Peripheral artery stent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |